216 related articles for article (PubMed ID: 33779292)
1. Thyrotropin Suppression for Papillary Thyroid Cancer: A Physician Survey Study.
Papaleontiou M; Chen DW; Banerjee M; Reyes-Gastelum D; Hamilton AS; Ward KC; Haymart MR
Thyroid; 2021 Sep; 31(9):1383-1390. PubMed ID: 33779292
[No Abstract] [Full Text] [Related]
2. Factors associated with physicians' recommendations for managing low-risk papillary thyroid cancer.
McDow AD; Roman BR; Saucke MC; Jensen CB; Zaborek N; Jennings JL; Davies L; Brito JP; Pitt SC
Am J Surg; 2021 Jul; 222(1):111-118. PubMed ID: 33248684
[TBL] [Abstract][Full Text] [Related]
3. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?
Tian T; Huang R; Liu B
Endocrine; 2019 Jul; 65(1):149-154. PubMed ID: 30924085
[TBL] [Abstract][Full Text] [Related]
4. Age-based factors modulating the required thyroxine dose to achieve thyrotropin suppression in intermediate-and high-risk papillary thyroid cancer.
Zhou RY; Li N; Tan HL; Tang N; Chen P; Liu M; Ou-Yang DJ; Qin ZE; Ai L; Wei B; Zhao YX; Chang S; Huang P
Front Endocrinol (Lausanne); 2023; 14():1126592. PubMed ID: 37388210
[TBL] [Abstract][Full Text] [Related]
5. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry.
Cooper DS; Specker B; Ho M; Sperling M; Ladenson PW; Ross DS; Ain KB; Bigos ST; Brierley JD; Haugen BR; Klein I; Robbins J; Sherman SI; Taylor T; Maxon HR
Thyroid; 1998 Sep; 8(9):737-44. PubMed ID: 9777742
[TBL] [Abstract][Full Text] [Related]
6. Adherence to ATA 2015 guidelines in the management of unifocal non-invasive papillary thyroid cancer: a clinical survey among endocrinologists and surgeons.
Or K; Benbassat C; Koren S; Shteinshneider M; Koren R; Cantrell D; Kummer E; Muallem Kalmovich L
Eur Arch Otorhinolaryngol; 2018 Nov; 275(11):2851-2859. PubMed ID: 30229453
[TBL] [Abstract][Full Text] [Related]
7. Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer.
Lee MC; Kim MJ; Choi HS; Cho SW; Lee GH; Park YJ; Park DJ
Endocrinol Metab (Seoul); 2019 Jun; 34(2):150-157. PubMed ID: 31099202
[TBL] [Abstract][Full Text] [Related]
8. Physician Specialties Involved in Thyroid Cancer Diagnosis and Treatment: Implications for Improving Health Care Disparities.
Radhakrishnan A; Reyes-Gastelum D; Abrahamse P; Gay B; Hawley ST; Wallner LP; Chen DW; Hamilton AS; Ward KC; Haymart MR
J Clin Endocrinol Metab; 2022 Feb; 107(3):e1096-e1105. PubMed ID: 34718629
[TBL] [Abstract][Full Text] [Related]
9. Endocrinologist-Perceived Factors Affecting the Transition of Thyroid Cancer Patients from Specialist to Primary Care Postcancer Treatment in Ontario, Canada.
Janmohamed N; Segal P; Corrado AM; Lofters A; Nguyen P; Townsley C; Zahedi A
Thyroid; 2021 Jun; 31(6):895-901. PubMed ID: 33121388
[No Abstract] [Full Text] [Related]
10. Multilevel Factors Associated With More Intensive Use of Radioactive Iodine for Low-Risk Thyroid Cancer.
Wallner LP; Banerjee M; Reyes-Gastelum D; Hamilton AS; Ward KC; Lubitz C; Hawley ST; Haymart MR
J Clin Endocrinol Metab; 2021 May; 106(6):e2402-e2412. PubMed ID: 33687063
[TBL] [Abstract][Full Text] [Related]
11. REFERRAL OF OLDER THYROID CANCER PATIENTS TO A HIGH-VOLUME SURGEON: RESULTS OF A MULTIDISCIPLINARY PHYSICIAN SURVEY.
Papaleontiou M; Gauger PG; Haymart MR
Endocr Pract; 2017 Jul; 23(7):808-815. PubMed ID: 28534681
[TBL] [Abstract][Full Text] [Related]
12. Adoption of Active Surveillance for Very Low-Risk Differentiated Thyroid Cancer in the United States: A National Survey.
Pitt SC; Yang N; Saucke MC; Marka N; Hanlon B; Long KL; McDow AD; Brito JP; Roman BR
J Clin Endocrinol Metab; 2021 Mar; 106(4):e1728-e1737. PubMed ID: 33373458
[TBL] [Abstract][Full Text] [Related]
13. Thyrotropin Suppressive Therapy for Low-Risk Small Thyroid Cancer: A Propensity Score-Matched Cohort Study.
Park S; Kim WG; Han M; Jeon MJ; Kwon H; Kim M; Sung TY; Kim TY; Kim WB; Hong SJ; Shong YK
Thyroid; 2017 Sep; 27(9):1164-1170. PubMed ID: 28699428
[TBL] [Abstract][Full Text] [Related]
14. Patient Requests for Tests and Treatments Impact Physician Management of Hypothyroidism.
Esfandiari NH; Reyes-Gastelum D; Hawley ST; Haymart MR; Papaleontiou M
Thyroid; 2019 Nov; 29(11):1536-1544. PubMed ID: 31436135
[No Abstract] [Full Text] [Related]
15. Factors influencing TSH suppression efficacy in postoperative papillary thyroid carcinoma patients: a retrospective cohort study.
Zhang Q; Zhong ZZ; Wu T; He YQ
BMC Surg; 2024 May; 24(1):133. PubMed ID: 38702652
[TBL] [Abstract][Full Text] [Related]
16. The Recovery of Thyroid Function in Low-Risk Papillary Thyroid Cancer After Lobectomy: A 3-Year Follow-Up Study.
Dou Y; Chen Y; Hu D; Su X
Front Endocrinol (Lausanne); 2020; 11():619841. PubMed ID: 33633689
[TBL] [Abstract][Full Text] [Related]
17. Barriers to the Use of Active Surveillance for Thyroid Cancer Results of a Physician Survey.
Hughes DT; Reyes-Gastelum D; Ward KC; Hamilton AS; Haymart MR
Ann Surg; 2022 Jul; 276(1):e40-e47. PubMed ID: 33074908
[TBL] [Abstract][Full Text] [Related]
18. IS IT WORTH SUPPRESSING TSH IN LOW- AND INTERMEDIATE-RISK PAPILLARY THYROID CANCER PATIENTS BEFORE THE FIRST DISEASE ASSESSMENT?
Lamartina L; Montesano T; Falcone R; Biffoni M; Grani G; Maranghi M; Ciotti L; Giacomelli L; Ramundo V; Lomonaco C; Di Gioia CR; Piernatale L; Ronga G; Durante C
Endocr Pract; 2019 Feb; 25(2):165-169. PubMed ID: 30383494
[TBL] [Abstract][Full Text] [Related]
19. Prescribing Therapy for Hypothyroidism: Influence of Physician Characteristics.
Jonklaas J; Tefera E; Shara N
Thyroid; 2019 Jan; 29(1):44-52. PubMed ID: 30375273
[TBL] [Abstract][Full Text] [Related]
20. [Hormonal therapy in differentiated carcinoma of the thyroid gland].
Francia G; Davì MV; Petroziello A; Sussi PL
Chir Ital; 1994; 46(4):56-8. PubMed ID: 7882445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
